TJX
62
3
PG
48
7
CTSH
65
2
EQR
54
4
PVH
65
-3
HCP
76
2
MAR
72
3
NEE
50
4
AIZ
73
4
BF.B
25
-3
URI
72
3
ABBV
55
-4
AIG
42
-2
SRE
68
4
ADM
17
-3
COST
66
6
NKE
30
2
PRU
54
-2
AMGN
47
3
WU
22
2
TJX
62
3
PG
48
7
CTSH
65
2
EQR
54
4
PVH
65
-3
HCP
76
2
MAR
72
3
NEE
50
4
AIZ
73
4
BF.B
25
-3
URI
72
3
ABBV
55
-4
AIG
42
-2
SRE
68
4
ADM
17
-3
COST
66
6
NKE
30
2
PRU
54
-2
AMGN
47
3
WU
22
2
Financhill
Back

Beam Therapeutics 10K Form

Buy
64

BEAM
Beam Therapeutics

Last Price:
27.02
Seasonality Move:
54.38%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-08 10Q BEAM/Beam Therapeutics Quarterly
2023-08-08 10Q BEAM/Beam Therapeutics Quarterly
2023-05-10 10Q BEAM/Beam Therapeutics Quarterly
2022-11-07 10Q BEAM/Beam Therapeutics Quarterly
2022-08-09 10Q BEAM/Beam Therapeutics Quarterly
2022-05-09 10Q BEAM/Beam Therapeutics Quarterly

Receive BEAM News And Ratings

See the #1 stock for the next 7 days that we like better than BEAM

BEAM Financial Statistics

Sales & Book Value

Annual Sales: $377.71M
Cash Flow: $-89.7M
Price / Cash Flow: 0
Annual Sales: $9.58
Price / Book: 2.83

Profitability

EPS (TTM): -1.76000
Net Income (TTM): $-143.59M
Gross Margin: $1.48B
Return on Equity: -16.62%
Return on Assets: -10.97%

Beam Therapeutics Earnings Forecast

Key Beam Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for BEAM is 58.08%.
  • The Selling, General & Administrative Expenses for BEAM have been equal to 30.93% of Gross Profit Margin.
  • The Research & Development expenses have been 115.80% of Revenue.
  • The Interest Expense is -0.24% of Operating Income.
  • The Net Earning history of BEAM is -35.09% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 6 years.

Beam Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BEAM
CUSIP: 07373V
Website: beamtx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.69
Quick Ratio: 5.57

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BEAM Technical Analysis vs Fundamental Analysis

Buy
64
Beam Therapeutics (BEAM) is a Buy

Is Beam Therapeutics a Buy or a Sell?

  • Beam Therapeutics stock is rated a Buy
    The current Beam Therapeutics [BEAM] share price is $27.06. The Score for BEAM is 64, which is 28% above its historic median score of 50, and infers lower risk than normal.